Analysis Research

 
Stock Quotes for Analysis Research top ^
  • Industry: Software - Application
  • Sector: Technology
  • Stock Type: Classic Growth
Sign-up for iaic investment picks
  • Industry: Software - Application
  • Sector: Technology
  • Stock Style: Large Core
  • Stock Type: Slow Growth
Sign-up for iaic investment picks

 
Fund Quotes for Analysis Research top ^
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for flsmx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsfx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsix investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsrx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 1 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for FLSLX investment picks

 
News Articles for Analysis Research top ^
2015/1/29
3M Food Safety announced today that two of its 3M™ Molecular Detection Assays, Listeria monocytogenes and Listeria species, have been approved for First Action Official Method of Analysis SM distinction by AOAC INTERNATIONAL (OMA method numbers 2014.07 and 2014.06, respectively). The scope of the validations cover a variety of food matrices including full fat cottage cheese, chocolate milk, beef hot dogs, deli turkey, and cold smoked salmon, as well as stainless steel and concrete environmental surfaces.
Sign-up for 3M Molecular Detection Assays Listeria monocytogenes and Listeria Receive First Action Official Methods of Analysis Designations by AOAC INTERNATIONAL investment picks
2015/1/5
The pension funded status of the nation’s largest corporate sponsors reversed direction in 2014, dropping nine percentage points as falling interest rates (which increased liabilities) and the impact of new mortality tables partially offset strong returns on pension plan assets, according to a new analysis by global professional services company Towers Watson (NYSE, NASDAQ: TW). The Towers Watson analysis examined pension plan data for the 411 Fortune 1000 companies that sponsor U.S. tax-qualified defined benefit pension plans and have a December fiscal-year-end date.
Sign-up for Corporate Pension Plan Funding Levels Declined in 2014, Reversing Much of 2013 Gains, Towers Watson Analysis Finds investment picks
2015/2/16
WILSONVILLE, Ore.
Sign-up for Mentor Graphics Signs Agreement with CADD Edge to Distribute Electronic Design and Analysis Products investment picks
2014/12/11
CA Technologies (NASDAQ:CA) today announced it has been positioned by Gartner, Inc. in the Leaders quadrant of the “ Magic Quadrant for Integrated IT Portfolio Analysis Applications ”* for the third year in a row.
Sign-up for CA Technologies Positioned as “Leader” in Gartner Magic Quadrant Report for Integrated IT Portfolio Analysis Applications for Third Consecutive Year investment picks
2015/1/15
BEST, Netherlands and CORRALES, N.M. , Jan.
Sign-up for Philips and Indica Labs Team to Accelerate Cancer Research through Advanced Image Analysis investment picks
2015/2/10
-- CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint -- Enrollment to be completed in 2015 with final data in Q3 2016 --
Sign-up for Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus investment picks
2014/12/6
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE , Dec.
Sign-up for CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers investment picks
2014/12/2
Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program and a U.S. Treatment IND Study DUBLIN , Dec.
Sign-up for Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting investment picks
2014/12/15
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and the treatment of localized prostate cancer, today announced findings from an administrative interim analysis of efficacy in its ongoing Phase 3 “PLUS-1” trial of PRX302 as a treatment for lower urinary tract symptoms of BPH.
Sign-up for Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia investment picks
2014/12/16
- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study - BERKELEY HEIGHTS, N.J., Dec.
Sign-up for Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Analysis Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Anadarko Shares  |  Next: Analysis Services